Faromed Labs

Faromed is a clinical-stage biopharmaceutical company focused on the development and commercialization of faropenem daloxate, a novel oral penem antibiotic. The company's lead candidate, FRPM-101, is designed to address serious bacterial infections, including those caused by multi-drug resistant organisms and biothreat pathogens like Burkholderia pseudomallei. Faromed has received Orphan Drug and Fast Track designations from the FDA for the treatment of melioidosis, a life-threatening infection with limited oral treatment options. By leveraging the established safety profile of faropenem, which is approved in other global markets, the company aims to provide a critical oral alternative to intravenous carbapenems in the United States. Faromed is led by a team of experienced infectious disease experts dedicated to improving outcomes for patients with respiratory and systemic bacterial infections.